Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people.
This is a multicentre double-blind study of fluvoxamine versus mianserin in the treatment of major depressive episode in patients over 65 years of age. Fifty-seven patients received either fluvoxamine (100-200 mg daily) or mianserin (40-80 mg daily). There was no statistically significant difference in improvement between the 2 treatment groups as measured by the Montgomery-Asberg Depression Rating Scale. Eleven patients (7 in the fluvoxamine group and 4 in the mianserin group) discontinued treatment because of intolerance. No statistically significant differences were seen in biological parameters with either drug. Both drugs improved the symptoms of depression though the overall response rate was not outstanding. The side effects profile for the fluvoxamine was contrary to previous studies in that frequent nausea and vomiting were not seen.
Phanjoo
A L
AL
Jardine Clinic, Royal Edinburgh Hospital, Scotland.
Wonnacott
S
S
Hodgson
A
A
D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000627:therapeutic use*; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D010091:Oximes; D008803:Mianserin; D016666:Fluvoxamine